Cargando…

Reengagement strategies for hepatitis C patients lost to follow-up: A randomized clinical trial

BACKGROUND AND AIMS: To achieve the World Health Organization’s goal of eliminating HCV by 2030, reengagement of lost to follow-up cases is mandatory. However, there is lack of evidence concerning the best strategy. Our study evaluated the effectiveness, efficiency, predictive factors, and costs of...

Descripción completa

Detalles Bibliográficos
Autores principales: Morales-Arraez, Dalia, Hernández-Bustabad, Alberto, Reygosa Castro, Cristina, Benitez-Zafra, Federica, Nicolás-Pérez, David, Crespo, Orestes, Díaz-Flores, Felicitas, Hernández-Guerra, Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10538908/
https://www.ncbi.nlm.nih.gov/pubmed/37204411
http://dx.doi.org/10.1097/HC9.0000000000000080
_version_ 1785113399334535168
author Morales-Arraez, Dalia
Hernández-Bustabad, Alberto
Reygosa Castro, Cristina
Benitez-Zafra, Federica
Nicolás-Pérez, David
Crespo, Orestes
Díaz-Flores, Felicitas
Hernández-Guerra, Manuel
author_facet Morales-Arraez, Dalia
Hernández-Bustabad, Alberto
Reygosa Castro, Cristina
Benitez-Zafra, Federica
Nicolás-Pérez, David
Crespo, Orestes
Díaz-Flores, Felicitas
Hernández-Guerra, Manuel
author_sort Morales-Arraez, Dalia
collection PubMed
description BACKGROUND AND AIMS: To achieve the World Health Organization’s goal of eliminating HCV by 2030, reengagement of lost to follow-up cases is mandatory. However, there is lack of evidence concerning the best strategy. Our study evaluated the effectiveness, efficiency, predictive factors, and costs of 2 different strategies. METHODS: We identified patients positive for HCV antibodies without RNA requests from 2005 to 2018. Patients fulfilling trial criteria (NCT04153708) were randomized to (1) phone call or (2) letter of invitation to schedule an appointment, followed by switching strategy. RESULTS: Three hundred forty-five patients among 1167 lost to follow-up were identified. An analysis of the first 270 randomized patients (72% male, 51±13 y) showed a higher contact rate in the mail than in the phone call strategy (84.5% vs. 50.3%). In the intention-to-treat analysis, no differences were found related to appointment attendance (26.5% vs. 28.5%). Regarding efficiency, 3.1 letters and 8 phone calls were needed to successfully link 1 patient (p<0.001) but dropped down to 2.3 phone calls if we only considered the first call attempt (p=0.008). Prior specialist’s evaluation and HCV testing in the predirect-acting antiviral era were the only factors associated with no showing up for the appointment. The cost per patient was €621.3 (2.5 quality-adjusted life-years) in the phone call strategy and €611.8 (2.4 quality-adjusted life-years) in the mail letter strategy. CONCLUSIONS: Reengagement of patients with HCV is feasible, and equally effective with similar costs in both strategies. The mail letter was more efficient, except when only 1 phone call was considered. Prior specialist’s evaluation and testing in the predirect-acting antiviral era were factors associated with nonattendance to the appointment.
format Online
Article
Text
id pubmed-10538908
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-105389082023-09-29 Reengagement strategies for hepatitis C patients lost to follow-up: A randomized clinical trial Morales-Arraez, Dalia Hernández-Bustabad, Alberto Reygosa Castro, Cristina Benitez-Zafra, Federica Nicolás-Pérez, David Crespo, Orestes Díaz-Flores, Felicitas Hernández-Guerra, Manuel Hepatol Commun Original Article BACKGROUND AND AIMS: To achieve the World Health Organization’s goal of eliminating HCV by 2030, reengagement of lost to follow-up cases is mandatory. However, there is lack of evidence concerning the best strategy. Our study evaluated the effectiveness, efficiency, predictive factors, and costs of 2 different strategies. METHODS: We identified patients positive for HCV antibodies without RNA requests from 2005 to 2018. Patients fulfilling trial criteria (NCT04153708) were randomized to (1) phone call or (2) letter of invitation to schedule an appointment, followed by switching strategy. RESULTS: Three hundred forty-five patients among 1167 lost to follow-up were identified. An analysis of the first 270 randomized patients (72% male, 51±13 y) showed a higher contact rate in the mail than in the phone call strategy (84.5% vs. 50.3%). In the intention-to-treat analysis, no differences were found related to appointment attendance (26.5% vs. 28.5%). Regarding efficiency, 3.1 letters and 8 phone calls were needed to successfully link 1 patient (p<0.001) but dropped down to 2.3 phone calls if we only considered the first call attempt (p=0.008). Prior specialist’s evaluation and HCV testing in the predirect-acting antiviral era were the only factors associated with no showing up for the appointment. The cost per patient was €621.3 (2.5 quality-adjusted life-years) in the phone call strategy and €611.8 (2.4 quality-adjusted life-years) in the mail letter strategy. CONCLUSIONS: Reengagement of patients with HCV is feasible, and equally effective with similar costs in both strategies. The mail letter was more efficient, except when only 1 phone call was considered. Prior specialist’s evaluation and testing in the predirect-acting antiviral era were factors associated with nonattendance to the appointment. Lippincott Williams & Wilkins 2023-05-18 /pmc/articles/PMC10538908/ /pubmed/37204411 http://dx.doi.org/10.1097/HC9.0000000000000080 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (https://creativecommons.org/licenses/by/4.0/) (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/)
spellingShingle Original Article
Morales-Arraez, Dalia
Hernández-Bustabad, Alberto
Reygosa Castro, Cristina
Benitez-Zafra, Federica
Nicolás-Pérez, David
Crespo, Orestes
Díaz-Flores, Felicitas
Hernández-Guerra, Manuel
Reengagement strategies for hepatitis C patients lost to follow-up: A randomized clinical trial
title Reengagement strategies for hepatitis C patients lost to follow-up: A randomized clinical trial
title_full Reengagement strategies for hepatitis C patients lost to follow-up: A randomized clinical trial
title_fullStr Reengagement strategies for hepatitis C patients lost to follow-up: A randomized clinical trial
title_full_unstemmed Reengagement strategies for hepatitis C patients lost to follow-up: A randomized clinical trial
title_short Reengagement strategies for hepatitis C patients lost to follow-up: A randomized clinical trial
title_sort reengagement strategies for hepatitis c patients lost to follow-up: a randomized clinical trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10538908/
https://www.ncbi.nlm.nih.gov/pubmed/37204411
http://dx.doi.org/10.1097/HC9.0000000000000080
work_keys_str_mv AT moralesarraezdalia reengagementstrategiesforhepatitiscpatientslosttofollowuparandomizedclinicaltrial
AT hernandezbustabadalberto reengagementstrategiesforhepatitiscpatientslosttofollowuparandomizedclinicaltrial
AT reygosacastrocristina reengagementstrategiesforhepatitiscpatientslosttofollowuparandomizedclinicaltrial
AT benitezzafrafederica reengagementstrategiesforhepatitiscpatientslosttofollowuparandomizedclinicaltrial
AT nicolasperezdavid reengagementstrategiesforhepatitiscpatientslosttofollowuparandomizedclinicaltrial
AT crespoorestes reengagementstrategiesforhepatitiscpatientslosttofollowuparandomizedclinicaltrial
AT diazfloresfelicitas reengagementstrategiesforhepatitiscpatientslosttofollowuparandomizedclinicaltrial
AT hernandezguerramanuel reengagementstrategiesforhepatitiscpatientslosttofollowuparandomizedclinicaltrial